AYTU
Aytu BioPharma, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$2.21
−3.28%Year over year
Reported trailing growth
- Revenue
- -18.2%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +127.1%
- Operating cash flow
- +130.4%
Forward estimates
Based on analyst estimates
- Revenue
- +23.7%
- EBITDA
- +133.8%
- EPS
- +105.8%
Three-year CAGR
- Revenue
- -11.8%
- EBITDA
- —
- EBIT
- —
- Net income
- +14.4%
- EPS
- +24.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026